Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Major shareholder announcement
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments.Per November 21, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,464,124 shares, corresponding to 5.01% (previously 4.94%) of the total share capital attached to shares. The combined total of share...
Nasdaq GlobeNewswire
25/11/2024
Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance…
"We are thrilled with a financing round of this magnitude and the support shown from such a strong group of investors as we continue to advance our pipeline of breakthrough ADCs for the treatment of underserved cancers," said Michael Pehl, Chief Executive Officer of Adcendo. "The excitement in the ADC space paired with our team's experience and passion for the underlying science motivates us to continue pushing our programs forward into the clinic. We look forward to achieving key…
PR Newswire
25/11/2024
Novo Holdings to acquire Benchmark Genetics, a leader in aquaculture genetics
The Company's core genetics offering drives resource-efficiency in fish and shrimp farming by addressing key production challenges including growth rates, feed conversion and disease resistance. By combining its long-established breeding programs and the latest genomic tools, Benchmark Genetics help aquaculture producers increase quality, yield, health, and animal welfare. The Company's core genetics offering drives resource-efficiency in fish and shrimp farming by addressing key production...
PR Newswire
25/11/2024
WaterWipes® announces Pure Foundation Fund 2024 winners
Giving parents and fellow HCPs the chance to say 'thank you' to those who have gone above and beyond, WaterWipes® focused this year's Pure Foundation Fund on HCPs who have helped care for babies born prematurely or admitted into the NICU. Unlike previous years, voters could nominate not just an individual, but also an entire team or unit. Giving parents and fellow HCPs the chance to say 'thank you' to those who have gone above and beyond, WaterWipes® focused this year's Pure Foundation Fund…
PR Newswire
25/11/2024
French hospital joins regional pathology solution from Sectra to enhance…
The hospitals complement their use of microscopes with a digital solution, allowing the pathologists to enhance review and collaboration around cases as well as benefit from AI tools. The digital workflow provides instant and, if needed, remote access to digital images of tissue samples instead of relying on physical glass slides reviewed in microscopes. The hospitals complement their use of microscopes with a digital solution, allowing the pathologists to enhance review and collaboration...
PR Newswire
25/11/2024
J INTS BIO and MD Anderson Collaborate on the Development of Brain Tumor…
'JIN-001' targets glioblastoma (GBM) cells by significantly enhancing the efficacy of radiation therapy and chemotherapy. As a selective inhibitor of HSP90 (Heat Shock Protein 90), its primary advantage lies in its ability to cross the blood-brain barrier (BBB), which typically hinders therapeutic agents from reaching the brain. While the BBB serves as a protective mechanism for the brain, it also presents a major obstacle for drug delivery. JIN-001 overcomes this limitation, directly attacking…
PR Newswire
25/11/2024
Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial…
Longer-term 96-week results from Scemblix ®ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data Late-breaking Kisqali ® * 4-year analysis on distant disease-free survival in key subgroups with HR+/HER2- early breast cancer from Phase III NATALEE trial also to be presentedPipeline updates demonstrate advancement in research and development programs in hematologic diseases and cancers Basel, November...
Nasdaq GlobeNewswire
25/11/2024
Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed…
On November 25, Hanmi announced that it presented the research and clinical progress of BH3120 in a poster session at the Society for Immunotherapy of Cancer (SITC) conference, held in Houston, USA, from November 6 to 10. OnNovember 25, Hanmi announced that it presented the research and clinical progress of BH3120 in a poster session at the Society for Immunotherapy of Cancer (SITC) conference, held inHouston,USA, fromNovember 6 to 10. BH3120 is a novel anticancer drug based on...
PR Newswire
25/11/2024
Servier's Vorasidenib Receives Approval as Clinical Urgently Needed Drug to be…
Gliomas represent the most common primary malignant brain tumors and the most common tumors of the central nervous system. Currently, treatment options for glioma are very limited. Even with a multi-modal approach combining surgical resection, concurrent chemoradiation and adjuvant chemotherapy, over 90% of glioma patients experience recurrence and disease progression.[1] Gliomas represent the most common primary malignant brain tumors and the most common tumors of the central nervous system...
PR Newswire
24/11/2024
Riyadh Conference Marks New Era in Conjoined Twins Medical Care and Support
In his opening remarks, H.E. Dr. Abdullah bin Abdulaziz Al Rabeeah, Head of the Saudi Conjoined Twins Programme, Advisor to the Saudi Royal Court, and Supervisor General of KSrelief, emphasized the commitment of the programme's surgical and medical teams to the programme. "We all pledge to the leadership of our beloved country that we will continue our journey of humanitarian giving and strive to add to our decades of scientific experience to help even more conjoined twins live healthy…
PR Newswire
24/11/2024
Boehringer Ingelheim launches VETMEDIN® Solution (pimobendan oral solution)…
Now pet owners have a convenient, new management option to support the hearts of dogs with CHF: a liquid version of VETMEDIN®, one of the leading canine cardiology medications in the world. Previous studies have shown that VETMEDIN® could help increase the survival time and quality of life in dogs due to MMVD or DCM.2,3 Now pet owners have a convenient, new management option to support the hearts of dogs with CHF: a liquid version of VETMEDIN ®, one of the leading canine...
PR Newswire
22/11/2024
Reporting of transactions made by persons discharging managerial…
Company announcement no. 11 - 2422 November 2024Reporting of transactions made by persons discharging managerial responsibilities, and persons closely associated with them, in NTG's shares In accordance with section 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation), NTG Nordic Transport Group A/S (“NTG”), CVR no. 12546106, hereby announces receipt of the following notification from persons...
Nasdaq GlobeNewswire
22/11/2024
COSRX Kicks Off Black Friday/Cyber Monday Sales with Up to 56% Off!
Advanced Snail 96 Mucin Power Essence Advanced Snail 96 Mucin Power Essence The TikTok viral COSRX Advanced Snail 96 Mucin Power Essence is formulated with snail mucin to protect the skin barrier from losing moisture. Skincare influencers and Amazon reviewers rave about the product for revitalizing and hydrating the skin without irritation. One shopper calls it "the VIP ticket to hydration town," since it will "keep your skin plump and moist, the perfect combination for…
PR Newswire
22/11/2024
Bioretec signed a new sales and distribution agreement to accelerate the…
As part of the next phase of the RemeOs™ Trauma Screw commercialization, Bioretec aims to sign more new local sales and distribution agreements to serve civilian hospitals in the U.S. while Spartan Medical continues to serve the military and veteran hospitals. As part of the next phase of the RemeOs ™Trauma Screw commercialization,Bioretec aims to sign more new local sales and distribution agreements to serve civilian hospitals in the U.S. while Spartan Medical continues to serve the...
PR Newswire
22/11/2024
Orion Research Foundation grants EUR 1,109,000 for research in 2025
Orion Research Foundation grants EUR 1,109,000 for research in 2025Press release 22 November, 2024 at 9.00 EET Orion Research Foundation sr is distributing EUR 1,109,000 in research grants based on applications for 2025. Orion Research Foundation awards grants of max EUR 50,000 for 19 researchers for postdoctoral research and max EUR 6,000 for 93 young researchers for doctoral dissertation work. Orion Research Foundation sr is annually distributing its return on investment and donations...
Nasdaq GlobeNewswire
22/11/2024
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, November 22, 2024-Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its third quarter financial results for the periods ended September...
Nasdaq GlobeNewswire
22/11/2024
Notice of AGM
DXS INTERNATIONAL PLC(AQSE: DXSP)Notice of 2024 Annual General Meeting The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce that its Annual General Meeting is scheduled to take place on Thursday 19 thDecember at Noon at Elm House, Tanshire Park, Shackleford Road. Elstead, Surrey GU8 6LB.For further information in relation to the AGM,...
Nasdaq GlobeNewswire
22/11/2024
Pharmaceutical Waste Management Market Analysis: Innovations Driving Sustainable…
Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-34A1606/Global_Pharmaceutical_Waste_Management_Market Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-34A1606/Global_Pharmaceutical_Waste_Management_Market Major Factors Driving the Growth of Pharmaceutical Waste Management Market: The pharmaceutical waste management market is witnessing robust growth due to the increasing generation of waste from drug production, healthcare...
PR Newswire
21/11/2024
Global Ceramic Ball Valve Market Analysis (2024-2030): Resilient Solutions for…
Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-5S9269/Global_Ceramic_Ball_Valve_Market Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-5S9269/Global_Ceramic_Ball_Valve_Market Major Factors Driving the Growth of Ceramic Ball Valve Market: The ceramic ball valve market is growing as industries recognize their durability, chemical resistance, and efficiency in demanding applications. Key factors driving growth include their...
PR Newswire
21/11/2024
Inventiva reports 2024 Third Quarter Financial Information¹
Cash and cash equivalents at €13.9 million, as of September 30, 2024.Revenues of €1.3 million for the first nine months of 2024.On July 18, 2024, Inventiva issued royalty certificates for an amount of €20.1 million.Considering the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the equity raise announced on October 14, 2024 2and the receipt of the $10 million milestone payment under the amended license and collaboration agreement...
Nasdaq GlobeNewswire
21/11/2024
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; November 21, 2024 –Genmab A/S(Nasdaq: GMAB) announced today that the Board decided to grant 10,273 restricted stock units and 10,853 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the...
Nasdaq GlobeNewswire
21/11/2024
Zero Candida Announces TSX Venture Exchange Listing Date
About Zero Candida About Zero Candida Zero Candida is focused on commercial exploitation of a number of patents and patent applications with respect to an AI smart tampon-like device, designed to treat Candidiasis and transfer the medical information via Wi-Fi to the doctor. ZC technology is a combination of a therapy light source with a selected wavelength and intensity and a transparent gel-based drug delivery system to maintain the optimum Ph level in the vagina. The device when used...
PR Newswire
21/11/2024
Embrace Sustainable Luxury: LILYSILK's Black Friday Delivers Discount on…
"LILYSILK is more than just elegance; we advocate a lifestyle of respect and care for our natural world," said David Wang, CEO of LILYSILK. "Our products surpass aesthetic appeal to fulfill the rising demand for high-quality, ethically and sustainably produced goods. This Black Friday, we invite our customers to select items that showcase their refined taste and dedication to environmental stewardship. LILYSILK's textiles allow consumers to enjoy both comfort and a positive impact…
PR Newswire
21/11/2024
Diamyd Medical hits a recruitment milestone in DIAGNODE-3 Phase 3 trial
180 enrolled patients ensures that at least 170 evaluable patients will be included in the planned early readout. This earlier readout is expected around March 2026 and is designed to provide the foundation for a potential BLA submission under the FDA's accelerated approval pathway. Recruitment efforts for the DIAGNODE-3 trial will continue to ensure comprehensive data collection from the full trial cohort of approximately 330 patients that will be followed for a total of 24 months. 180...
PR Newswire
21/11/2024
Altri Comunicati
